SPRB Stock Overview
A biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Spruce Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.49 |
| 52 Week High | US$5.95 |
| 52 Week Low | US$0.41 |
| Beta | 2.37 |
| 11 Month Change | -11.69% |
| 3 Month Change | 2.85% |
| 1 Year Change | -63.90% |
| 33 Year Change | -82.46% |
| 5 Year Change | n/a |
| Change since IPO | -97.11% |
Recent News & Updates
Shareholder Returns
| SPRB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.8% | -6.5% | -1.0% |
| 1Y | -63.9% | 14.6% | 30.3% |
Return vs Industry: SPRB underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: SPRB underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| SPRB volatility | |
|---|---|
| SPRB Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SPRB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SPRB's weekly volatility has decreased from 15% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 22 | Javier Szwarcberg | www.sprucebiosciences.com |
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial.
Spruce Biosciences, Inc. Fundamentals Summary
| SPRB fundamental statistics | |
|---|---|
| Market cap | US$20.24m |
| Earnings (TTM) | -US$39.43m |
| Revenue (TTM) | US$7.10m |
2.9x
P/S Ratio-0.5x
P/E RatioIs SPRB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPRB income statement (TTM) | |
|---|---|
| Revenue | US$7.10m |
| Cost of Revenue | US$36.06m |
| Gross Profit | -US$28.96m |
| Other Expenses | US$10.47m |
| Earnings | -US$39.43m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.95 |
| Gross Margin | -407.83% |
| Net Profit Margin | -555.23% |
| Debt/Equity Ratio | 4.2% |
How did SPRB perform over the long term?
See historical performance and comparison